Company Name: |
Shanghai YuanQi Biotechnology Co., Ltd.
|
Tel: |
+86-2332782371 +86-18120098618 |
Email: |
sales@adobechem.com |
Products Intro: |
Product Name:AZD3965 CAS:733809-45-5 Purity:>98% Package:5mg/;10mg/;50mg/;100mg/
|
Company Name: |
ShangHai Biochempartner Co.,Ltd
|
Tel: |
17754423994 17754423994 |
Email: |
2853530910@QQ.com |
Products Intro: |
Product Name:AZD3965 CAS:733809-45-5 Purity:98% HPLC LCMS Package:100mg;1g
|
Company Name: |
Shanghai Biopharmaleader Co., Ltd.
|
Tel: |
+86 18721201413 |
Email: |
sales@biopharmaleader.com |
Products Intro: |
Product Name:AZD-3965 CAS:733809-45-5 Purity:98%HPLC Package:10g,100g
|
|
| AZD-3965 Basic information |
Product Name: | AZD-3965 | Synonyms: | AZD-3965;5-[[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-6-[[3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione;(S)-5-(4-hydroxy-4-methylisoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-((3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione;Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 5-[[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-3-methyl-1-(1-methylethyl)-6-[[3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]- | CAS: | 733809-45-5 | MF: | C21H24F3N5O5S | MW: | 515.51 | EINECS: | | Product Categories: | | Mol File: | 733809-45-5.mol | |
| AZD-3965 Chemical Properties |
Melting point | >140°C (dec.) | Boiling point | 723.1±70.0 °C(Predicted) | density | 1.483±0.06 g/cm3(Predicted) | storage temp. | -20°C, Inert atmosphere | solubility | DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly) | form | Solid | pka | 10.92±0.50(Predicted) | color | Off-White to Pale Yellow |
| AZD-3965 Usage And Synthesis |
Uses | AZD 3965 is a monocarboxylate transporter 1 (MCT1) inhibitor. | Enzyme inhibitor | This orally bioavailable MCT1 inhibitor (FW = 515.51 g/mol; CASs = 733809-45-5 and 1448671-31-5), also named (S)-5-(4-hydroxy-4- methylisoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-((3-methyl-5-(tri fluoromethyl)-1H-pyrazol-4-yl)methyl)-thieno[2,3-d]pyrimidine-2,4(1H, 3H) -dione, selectively targets the Monocarboxylate Transporter-1 (IC50 = 1.6 nM) and is ~6x less active toward MCT2. AZD3965 does not inhibit MCT4, even at 10 μM. MCT1 and MCT4 are primarily involved in lactate transport, targeting highly glycolytic cancer cells, especially those that are hypoxic. The latter property suggests that the combined use with a vascular-disrupting anticancer agent (such as combrestatin) may improve the inhibitory action of AZD-3965 against cancer cells. |
| AZD-3965 Preparation Products And Raw materials |
|